ArticleTranslational cancer research2025
Adagrasib in the treatment of KRAS
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In the phase II KRYSTAL-1 randomized clinical trial, adagrasib demonstrated clinical efficacy in patients with previously treated KRAS Methods: Based on the results obtained from the KRYSTAL-1 trial, a partitioned survival model was utilized to simulate the disease progression of patients receiving either adagrasib or conventional chemotherapy. Costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) were calculated with a willingness-to-pay (WTP) threshold of $150,000 (U.S. dollar) per QALY. Both univariate and probabilistic sensitivity analyses were carried out to analyze the robustness of the model. Results: Adagrasib achieved additional 0.33593 QALYs with additional costs of $306,775 compared to chemotherapy, resulting in an ICER of $913,211/QALY. Univariate sensitivity analysis showed that the utility value of progression-free survival (PFS) and cost of adagrasib had the greatest impact on the outcomes. Probability sensitivity analysis indicated that adagrasib was not considered cost-effective when using a WTP threshold of $150,000 per QALY. Conclusions: In this model, adagrasib was not considered to be cost-effective compared to chemotherapy for previously treated KRAS
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.